Markets:

Overview

News

Currencies

International

Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

21.25 +0.59 (+2.86%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 3, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)

April 26, 2024

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results

April 23, 2024

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

The 5 Stocks Most Sold By Insiders This Year

April 16, 2024

Insiders are selling these 5 stocks increased as their markets advanced, and gains may be capped. Long-term outlooks are positive for growth and share prices.

Via MarketBeat

Expert Ratings For Apellis Pharmaceuticals ↗

April 15, 2024

Via Benzinga

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,000 Today ↗

April 10, 2024

Via Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,000 Today ↗

March 29, 2024

Via Benzinga

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 04, 2024

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

April 01, 2024

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals ↗

March 27, 2024

Via Benzinga

Peering Into Apellis Pharmaceuticals's Recent Short Interest ↗

March 15, 2024

Via Benzinga

Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (18 Ratings) ↗

February 28, 2024

Via Benzinga

Earnings Scheduled For February 27, 2024 ↗

February 27, 2024

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.

Via Benzinga

Here's How Much You Would Have Made Owning Apellis Pharmaceuticals Stock In The Last 5 Years ↗

February 22, 2024

Via Benzinga

$1000 Invested In Apellis Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗

February 05, 2024

Via Benzinga

Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor

March 11, 2024

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 06, 2024

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments

March 06, 2024

Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place

Via MarketBeat

Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know ↗

January 30, 2024

Via Benzinga

Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (12 Ratings) ↗

January 09, 2024

Via Benzinga

ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

February 28, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

February 27, 2024

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

February 26, 2024

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results

February 20, 2024

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2024

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Monday ↗

February 05, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application

January 26, 2024

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Netflix To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

January 24, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Netflix To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

January 17, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 15, 2024

Via Benzinga

Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues

January 08, 2024

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.